Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Open Label Evaluation of the PK and PD of Dotinurad and Drug-Drug Interaction of Dotinurad and Allopurinol in U.S. Patients With Gout and Hyperuricemia

NCT06056570 is registered in ClinicalTrials.gov with Urica Therapeutics Inc. as lead sponsor.

NCT NCT06056570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06056570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Open Label Evaluation of the PK and PD of Dotinurad and Drug-Drug Interaction of Dotinurad and Allopurinol in U.S. Patients With Gout and Hyperuricemia
Lead sponsor
Urica Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 4, 2023
Completion date
July 9, 2024
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gout, hyperuricemia